TY - JOUR
T1 - Movement Through Chemotherapy Delay to Initiation Among Breast Cancer Patients
T2 - A Qualitative Analysis
AU - Housten, Ashley J.
AU - Malinowski, Catalina
AU - Paredes, Edna
AU - Harris, Cassandra L.
AU - McNeill, Lorna H.
AU - Chavez-Macgregor, Mariana
N1 - Funding Information:
This research was supported by Conquer Cancer, The ASCO Foundation, BCRF and NIH/NCIP30CA016672. MCM is supported by Susan G. KomenSAC150061, CPRIT-RP160674. AJH is supported by R00MD011485. CM is supported by Susan G. KomenGTDR17498270 and the Duncan Family Institute.
Funding Information:
This research was supported by Conquer Cancer, The ASCO Foundation, BCRF and NIH/NCI P30CA016672. MCM is supported by Susan G. Komen SAC150061, CPRIT-RP160674. AJH is supported by R00MD011485. CM is supported by Susan G. Komen GTDR17498270 and the Duncan Family Institute.
Publisher Copyright:
© 2022 Housten et al.
PY - 2022
Y1 - 2022
N2 - Purpose: (Neo) adjuvant chemotherapy decreases the risk of recurrence and improves overall survival among breast cancer patients; however, delays in chemotherapy initiation are associated with adverse health outcomes. The causes of delay are complex and include interrelated social, economic, cultural, environmental, and health system factors. Project Start was a qualitative study designed to assess and identify the multilevel factors contributing to the barriers and facilitators of initiating chemotherapy. Patients and Methods: Women diagnosed with primary invasive breast cancer who experienced ≥ 60 day delay in (neo) adjuvant chemotherapy initiation were included. Participants completed semi-structured interviews exploring barriers and facilitators to starting chemotherapy. Interviews were transcribed and coded to identify themes using the Sort and Sift, Think and Shift analytic approach. This analysis included thorough examination of the data by advancing through iterative analytic phases to identify core topics within and across transcripts. Results: We enrolled (N=22) participants with median age at diagnosis 53.5 years (range 27- 70) who identified as Latina (n=8), Black (n=5), and non-Latina White (n=9). Participants described a common chemotherapy initiation process reflecting their unique needs as they transitioned through four stages: 1) receiving diagnosis and treatment recommendations; 2) processing treatment options; 3) “Flipping the Switch”; and 4) activating treatment and engaging in care. Limited explicit insight into their chemotherapy delay was expressed. Engagement across the self-, family-, community-, and medical-realms revealed interlinked and pivotal sources of support that helped participants navigate toward initiating chemotherapy. Specifically, the overarching themes included logistical, emotional, financial, and social sources of support and the relationship of these sources of support to participants’ perceived self-efficacy to move toward initiating treatment. Conclusion: Activating women to be engaged in the treatment process across multiple levels appeared to facilitate initiating chemotherapy. Multilevel interventions that engage the patient, family, community, and medical team may support the initiation of timely chemotherapy.
AB - Purpose: (Neo) adjuvant chemotherapy decreases the risk of recurrence and improves overall survival among breast cancer patients; however, delays in chemotherapy initiation are associated with adverse health outcomes. The causes of delay are complex and include interrelated social, economic, cultural, environmental, and health system factors. Project Start was a qualitative study designed to assess and identify the multilevel factors contributing to the barriers and facilitators of initiating chemotherapy. Patients and Methods: Women diagnosed with primary invasive breast cancer who experienced ≥ 60 day delay in (neo) adjuvant chemotherapy initiation were included. Participants completed semi-structured interviews exploring barriers and facilitators to starting chemotherapy. Interviews were transcribed and coded to identify themes using the Sort and Sift, Think and Shift analytic approach. This analysis included thorough examination of the data by advancing through iterative analytic phases to identify core topics within and across transcripts. Results: We enrolled (N=22) participants with median age at diagnosis 53.5 years (range 27- 70) who identified as Latina (n=8), Black (n=5), and non-Latina White (n=9). Participants described a common chemotherapy initiation process reflecting their unique needs as they transitioned through four stages: 1) receiving diagnosis and treatment recommendations; 2) processing treatment options; 3) “Flipping the Switch”; and 4) activating treatment and engaging in care. Limited explicit insight into their chemotherapy delay was expressed. Engagement across the self-, family-, community-, and medical-realms revealed interlinked and pivotal sources of support that helped participants navigate toward initiating chemotherapy. Specifically, the overarching themes included logistical, emotional, financial, and social sources of support and the relationship of these sources of support to participants’ perceived self-efficacy to move toward initiating treatment. Conclusion: Activating women to be engaged in the treatment process across multiple levels appeared to facilitate initiating chemotherapy. Multilevel interventions that engage the patient, family, community, and medical team may support the initiation of timely chemotherapy.
KW - Breast cancer
KW - Care delivery
KW - Chemotherapy
KW - Oncology
KW - Patient perspectives
KW - Qualitative
KW - Treatment delay
UR - http://www.scopus.com/inward/record.url?scp=85129784064&partnerID=8YFLogxK
U2 - 10.2147/PPA.S350412
DO - 10.2147/PPA.S350412
M3 - Article
C2 - 35345541
AN - SCOPUS:85129784064
SN - 1177-889X
VL - 16
SP - 749
EP - 759
JO - Patient Preference and Adherence
JF - Patient Preference and Adherence
ER -